Newsletter Archive

  1. 03.26.24 -- Notable Public Comments On The FDA's Proposed Regulation For Laboratory Developed Tests 3/26/2024
    03/26/24 Laboratory Network Newsletter
  2. 03.12.24 -- FDA's CBER Issues Final Guidance For CAR T Cell Products 3/12/2024
    03/12/24 Laboratory Network Newsletter
  3. 02.27.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene 2/27/2024
    02/27/24 Laboratory Network Newsletter
  4. 02.13.24 -- FDA Issues Draft Guidance For Cell & Gene Therapy Potency Assurance 2/13/2024
    02/13/24 Laboratory Network Newsletter
  5. 01.23.24 -- 4 Strategies To Formulate Poorly Soluble APIs 1/23/2024
    01/23/24 Laboratory Network Newsletter
  6. 01.09.24 -- Introduction To The New ASTM E3418 1/9/2024
    01/09/24 Laboratory Network Newsletter
  7. 12.12.23 -- FDA Issues Draft Guidance On Remote Interactive Evaluations Of Drug Manufacturing And Bioresearch Monitoring Facilities 12/12/2023
    12/12/23 Laboratory Network Newsletter
  8. 11.28.23 -- Liquid Biopsy: The Next Evolution In Personalized Prostate Cancer Screening 11/28/2023
    11/28/23 Laboratory Network Newsletter
  9. 11.14.23 -- Using Automation For Antimicrobial Screening 11/14/2023
    11/14/23 Laboratory Network Newsletter
  10. 10.24.23 -- FDA's Proposed Laboratory-Developed Tests Rule Raises Many Questions But Provides Few Answers 10/24/2023
    10/24/23 Laboratory Network Newsletter